CGTX

Cognition Therapeutics, Inc. (CGTX) - Q2 2024 10-Q Summary

Business Context and Reporting Period

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing disease-modifying therapies for age-related degenerative diseases of the central nervous system (CNS) and retina. The company's lead product candidate, CT1812, targets the sigma-2 receptor complex to treat Alzheimer's disease and dementia with Lewy bodies. This report covers the quarterly period ended June 30, 2024.

Key Financial Metrics

Liquidity: As of June 30, 2024, the company held $28.5 million in cash and cash equivalents. The company has no debt obligations other than an insurance premium financing arrangement ($0.2 million outstanding) and operating lease liabilities.

Material Changes vs. Prior Period

• Increased Operating Expenses: Total operating expenses for the six months ended June 30, 2024, increased by $8.0 million (38%) compared to the same period in 2023. This was driven primarily by a $7.7 million increase in clinical program costs due to expanded Phase 2 trial activities.
• Grant Income Growth: Grant income increased by $1.9 million year-over-year for the six-month period, correlating with higher reimbursable costs incurred for clinical trials funded by the National Institute of Aging (NIA).
• Capital Raising: In March 2024, the company completed a follow-on public offering, raising net proceeds of approximately $11.9 million. Additionally, $0.4 million was raised via the At-The-Market (ATM) program during the six-month period.
• Subsidiary Liquidation: The company liquidated its wholly-owned Australian subsidiary in January 2024, resulting in a one-time loss on currency translation of $0.2 million recorded in the first half of 2024.

Guidance, Outlook, and Risks

Clinical Progress: In July 2024, the company reported results from the Phase 2 SHINE trial for CT1812 in Alzheimer's disease. While the trial did not achieve statistical significance on the primary endpoint, it showed a 39% slowing of cognitive decline compared to placebo and a favorable safety profile. The company expects to report topline results from the Phase 2 SHIMMER trial (Dementia with Lewy Bodies) by year-end 2024.

Going Concern Warning: Management has concluded that there is substantial doubt about the company's ability to continue as a going concern for the twelve months following the filing date. As of August 8, 2024, the company believes its cash balance is insufficient to fund operations for one year without additional financing.

Capital Needs: The company expects to continue incurring significant losses and will require substantial additional funding to advance clinical trials and operations. Future funding is expected to come from equity offerings, debt financing, or strategic collaborations. The company has approximately $34.3 million remaining under its ATM facility and $34.8 million available under its Lincoln Park equity line financing.

Investor Verification Checklist

• Cash Runway: Verify the specific timeline for cash depletion and the company's immediate plan to secure funding given the "substantial doubt" disclosure.
• Grant Dependency: Assess the sustainability of operations given the heavy reliance on NIA grants (approx. $57.3 million remaining available) and the risk of future grant reductions.
• Clinical Trial Outcomes: Monitor the upcoming SHIMMER trial results (expected late 2024) and any regulatory feedback regarding the SHINE trial data.
• Dilution Risk: Evaluate the potential dilution from future equity raises, noting the company has significant capacity remaining in its ATM and Lincoln Park facilities.
• Expense Trajectory: Review the continued increase in R&D expenses as the company scales Phase 2 trials and prepares for potential Phase 3 development.